Sensyne Health (SENS) Rating Reiterated by Peel Hunt

Peel Hunt restated their buy rating on shares of Sensyne Health (LON:SENS) in a research note released on Tuesday, April 2nd, ThisIsMoney.Co.Uk reports.

LON SENS remained flat at $GBX 178 ($2.33) on Tuesday. 1,875 shares of the company traded hands. The company has a market cap of $228.86 million and a PE ratio of 9.78. The company has a current ratio of 13.29, a quick ratio of 13.22 and a debt-to-equity ratio of 1.60.

Sensyne Health Company Profile

Sensyne Health plc, a healthcare technology company, engages in developing digital health software products in the United Kingdom. Its products include SEND, an early warning system that allows healthcare professionals to record vital sign observations, including blood pressure, pulse rate, oxygen saturation, temperature, respiratory rate, responsiveness, the presence of an oxygen mask, and a reason for concern by the nurse taking the observations; EDGE:COPD, a prescribed digital therapeutic for monitoring chronic obstructive pulmonary disease at home; GDm-Health, a patient-to-clinician system for the management of diabetes in pregnancy; and Support-HF, a digital health software system that underpins a remote patient management service for heart failure patients.

Further Reading: What are different types of coverage ratios?

Receive News & Ratings for Sensyne Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensyne Health and related companies with MarketBeat.com's FREE daily email newsletter.